Louisiana State Employees Retirement System Has $3.85 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Louisiana State Employees Retirement System trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,500 shares of the medical device company's stock after selling 3,700 shares during the period. Louisiana State Employees Retirement System's holdings in DexCom were worth $3,850,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC boosted its holdings in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after purchasing an additional 876,739 shares during the period. Two Sigma Advisers LP boosted its stake in DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock worth $76,659,000 after purchasing an additional 739,000 shares during the period. Intech Investment Management LLC boosted its stake in DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock worth $25,967,000 after purchasing an additional 369,587 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company's stock worth $66,352,000 after purchasing an additional 345,114 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Remove Ads

DexCom Stock Up 5.9 %

Shares of DexCom stock traded up $4.98 during midday trading on Friday, reaching $89.07. 7,591,102 shares of the company's stock traded hands, compared to its average volume of 3,361,682. The company has a market cap of $34.79 billion, a price-to-earnings ratio of 53.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The company's 50 day simple moving average is $82.44 and its 200 day simple moving average is $75.49. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. Equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 in the last ninety days. Insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DXCM. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday. Oppenheimer decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Royal Bank of Canada decreased their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Leerink Partners decreased their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.